spesolimab   Click here for help

GtoPdb Ligand ID: 12169

Synonyms: BI-655130 | BI655130 | spesolimab-sbzo | Spevigo®
Approved drug Immunopharmacology Ligand
spesolimab is an approved drug (FDA and EMA (2022))
Compound class: Antibody
Comment: Spesolimab (BI-655130) is a monoclonal antibody that disrupts interleukin-36 (IL-36)/IL-36 receptor signalling. Blocking this pathway is a molecular mechanism with potential to treat inflammatory diseases in skin and other epithelial tissues [2-3,5,7], since IL-36R expression is restricted to epithelial cells that are in direct contact with the environment, including those in the skin. Spesolimab (BI-655130) appears to be related to MAB92 which was reported by Boehringer Ingelheim in 2017 [6], but we have been unable to perform direct sequence matches. The heavy and light chain sequences for spesolimab (from its INN record) are claimed in Boehringer Ingelheim's patent US9023995B2 [4].
Click here for help
Immunopharmacology Comments
Interleukin-36 receptor (IL-36R) signalling is a causative mechanism in the pathogensis of generalized pustular psoriasis (GPP) [8]. Spesolimab-mediated antagonism of IL-36R activity effectively reduces flares in patients with GPP
Immunopharmacology Disease
Disease X-Refs Comment References
Netherton syndrome OMIM: 256500
Orphanet: ORPHA634
FDA orphan drug for NS (Feb 2024)